References
- Brinkmann U , KontermannRE. Bispecific antibodies. Science372(6545), 916–917 (2021).
- Wu X , DemarestSJ. Building blocks for bispecific and trispecific antibodies. Methods154, 3–9 (2019).
- US Food and Drug Administration . Pedras-VasconcelosJA. The immunogenicity of therapeutic proteins – what you don’t know can hurt YOU and the patient (2014). https://www.fda.gov/media/89071/download
- EMA . Guideline on Immunogenicity assessment of therapeutic proteins (2017). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
- CDER . Immunogenicity testing of therapeutic protein products – developing and validating assays for anti-drug antibody detection (2019). https://www.fda.gov/regulatory-informatioDC/Search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug
- Civoli F , KroenkeMA, ReynhardtKet al. Development and optimization of neutralizing antibody assays to monitor clinical immunogenicity. Bioanalysis4(22), 2725–2735 (2012).
- Wu B , ChungS, JiangX-R, McNallyJet al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J.18(6), 1335–1350 (2016).
- Chowdhury F , WilliamsA, JohnsonP. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J. Immunol. Methods340(1), 55–64 (2009).
- Caiazzo TM , SheaCM, JoyceAP. Critical reagent characterization and re-evaluation to ensure long-term stability: two case studies. Bioanalysis13(10), 807–815 (2021).
- Smith HW , ButterfieldA, SunD. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul. Toxicol. Pharmacol.49(3), 230–237 (2007).
- Xiang Y , ParngC, OlsonKet al. Neutralizing antibody assay development with high drug and target tolerance to support clinical development of an anti-TFPI therapeutic monoclonal antibody. AAPS J.21(3), 46 (2019).
- Lofgren JA , WalaI, KorenE, SwansonSJ, JingS. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J. Immunol. Methods308(1–2), 101–108 (2006).
- Gouty D , CaiCC, CaiXYet al. Recommendations for the development and validation of neutralizing antibody assays in support of biosimilar assessment. AAPS J.20(1), 25 (2017).
- Coddens A , SnoeckV, BontinckL, BuyseMA, PineSO. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics. J. Immunol. Methods487, 112896 (2020).